Q-linea AB (publ) announced that the company has finished the clinical trials for the drug Meropenem-Vaborbactam with strong results and is therefore able to claim IVDR compliance and add the drug to the existing BC-GN panel. The company expects commercial availability in Europe during Second Quarter 2024. Meropenem-Vaborbactam is a combination drug of a Carbapenem and a beta-lactamase inhibitor with enhanced activity against gram-negative organisms, particularly Enterobacterales with class A and C carbapenemases.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.355 SEK | +5.13% | -9.25% | -36.35% |
Apr. 26 | Q-Linea AB Receives FDA 510(k) Clearance for the ASTar® System | CI |
Mar. 13 | Q-linea AB Presents Strong ASTar Results At AMCLI | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-36.35% | 24.22M | |
-40.16% | 2.9B | |
+22.80% | 1.97B | |
+7.25% | 1.82B | |
+26.48% | 1.25B | |
-6.82% | 1.06B | |
-17.45% | 936M | |
-1.10% | 770M | |
-23.17% | 639M | |
+7.08% | 501M |
- Stock Market
- Equities
- QLINEA Stock
- News Q-linea AB
- Q-linea AB Expands the Gram-Negative Panel